Streetbeat News

Stock Prices

MRK

Merck's combination of favezelimab and Keytruda failed to meet the primary endpoint in a Phase 3 study for colorectal cancer, impacting its stock slightly. Despite this, analysts remain bullish on Merck with a 24% upside potential.

Portfolio Pulse from Vandana Singh

September 25, 2024 | 12:32 pm

BILI

GDS

JD

KBH

SFIX

TH

WVE

XPEV

ZLAB

Stitch Fix reported weak earnings, missing EPS estimates, leading to a 25.6% drop in pre-market trading. Other stocks like Target Hospitality, GDS Holdings, and KB Home also saw declines in pre-market trading.

Portfolio Pulse from Avi Kapoor

September 25, 2024 | 12:32 pm

MLYS

Mineralys Therapeutics has completed target enrollment for its pivotal Advance-HTN trial of lorundrostat for hypertension treatment. Topline data is expected in Q1 2025, with a virtual event scheduled for October 30th to discuss the trial and unmet needs in hypertension.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:31 pm

NLSP

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) is implementing a 1-for-40 reverse share split effective September 27, 2024. This will reduce the number of outstanding shares from 46,880,000 to approximately 1,172,000. The split will not affect shareholder ownership percentages, except for fractional shares.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:30 pm

AAPL

AFRM

AMZN

BBY

COST

EA

PYPL

SNE

SQ

WMT

XRT

Adobe forecasts a record $240.8 billion in e-commerce spending this holiday season, driven by consumer splurging and discounts. Electronics, apparel, and furniture will see significant sales, with mobile and BNPL purchases rising. Companies like Apple, Sony, Amazon, Best Buy, Walmart, and Costco are expected to benefit.

Portfolio Pulse from Shanthi Rexaline

September 25, 2024 | 12:29 pm

DSY

DSYWW

Big Tree Cloud Holdings Limited has regained compliance with Nasdaq's minimum market value of publicly held shares requirement, ensuring its continued listing on the Nasdaq Global Market.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:29 pm

SPY

The USA Building Permits for August were reported at 1.470 million, slightly below the estimated 1.475 million and above the prior 1.406 million.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:27 pm

FLUT

Flutter Entertainment has announced a strategic growth plan with a 2027 revenue target of ~$21B, a CAGR of 14%, and an adjusted EBITDA of over $5B. The company also plans a $5B share repurchase program. Flutter aims to leverage its global scale and local market leadership to achieve these goals.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:25 pm

AMD

APO

INTC

QCOM

Intel and AMD are in a competitive race against Nvidia in the semiconductor industry. Intel is facing challenges with a significant stock decline but potential investments from Apollo and acquisition talks with Qualcomm could signal a turnaround. AMD, on the other hand, has seen a stock surge due to its AI-driven growth, but recent volatility raises concerns. Intel offers a speculative high-risk, high-reward opportunity, while AMD presents a more stable investment with strong fundamentals.

Portfolio Pulse from Surbhi Jain

September 25, 2024 | 12:25 pm

GLMD

Galmed Pharmaceuticals has published the one-year results of its Phase 3 trial of Aramchol, showing significant anti-fibrotic effects in patients with NASH and fibrosis. The study, involving 150 patients, was published in Hepatology.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:21 pm